Peter Panhofer

Peter Panhofer

Auto-generated profile, based on publicly available information

Peter Panhofer

Sigmund Freud Universität (SFU), Professur für Komplementärmedizin

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Surgery for Obesity and Related Diseases
Verified
Journal Article
Closed access
Daniel FelsenreichDaniel Felsenreich
Daniel Felsenreich
FLFelix B. Langer
Felix B. Langer
RKRonald Kefurt
Ronald Kefurt
PPPeter Panhofer
Peter Panhofer
MSMartin Schermann
Martin Schermann
GPGerhard Prager
Gerhard Prager

1 April 2014 in International Journal of Surgery
Verified
Journal Article
Closed access
PPPeter Panhofer
Peter Panhofer
VFVeronika Ferenc
Veronika Ferenc
MSMichael Schütz
Michael Schütz
AGAndreas Gleiss
Andreas Gleiss
PDPeter Dubsky
Peter Dubsky
FFFlorian Fitzal
Florian Fitzal
There are no published data on standardized scoring systems for morbidity after breast cancer surgery. Aim of the study was to establish the Clavien Dindo Classification (CDC) as assessment tool and to identify risk factors for morbidity after breast surgery investigating new techniques including oncoplastic surgery and neoadjuvant chemotherapy. Between 2008 and 2010, data were retrospectively evaluated from 485 women with breast cancer who underwent surgery at a university hospital. The CDC was used to assess the severity of postoperative complications. Multivariable analyses were adjusted by body-mass index, smoking, diabetes mellitus and tumour size. Overall complications (CDC 1-4) were reported in 28.7%. Second surgery related to major complications (CDC 3-4) was mandatory in 4.7%. Axillary dissection was an independent predictor for CDC 1-4 in all patients (P = 0.008, OR of 1.81, 95%CI 1.17-2.82). We found no independent predictor for CDC 3-4. Oncoplastic surgery increased the rate of wound infections (P = 0.010, OR: 2.94, 95%CI 1.30-6.67) and necroses (P < 0.001, OR: 8.38, 95%CI 3.28-21.4). Axillary dissection elevated wound infection (P = 0.040, OR: 2.07, 95%CI 1.03-4.14) and seroma rates (P < 0.001, OR: 2.46, 95%CI 1.51-4.01). Neoadjuvant chemotherapy had no impact on morbidity. The CDC is a valid assessment tool for future clinical trials and may be useful for hospital quality control. While axillary dissection and oncoplastic surgery raised morbidity, no single factor predicted for morbidity related second surgery.

1 July 2005 in Archives of Surgery
Verified
Journal Article
Closed access
PDF file
CNChristoph Neumayer
Christoph Neumayer
PPPeter Panhofer
Peter Panhofer
JZJohannes Zacherl
Johannes Zacherl
GBGeorg Bischof
Georg Bischof
Research from JAMA Surgery — Effect of Endoscopic Thoracic Sympathetic Block on Plantar Hyperhidrosis

15 March 2008 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
PPPeter Panhofer
Peter Panhofer
BIBarbara Izay
Barbara Izay
MRMarkus Riedl
Markus Riedl
VFVeronika Ferenc
Veronika Ferenc
MPMartin Ploder
Martin Ploder
PGPeter Götzinger
Peter Götzinger

1 August 2021 in Complementary Therapies in Clinical Practice
Verified
Journal Article
Closed access
MTMichael Takacs
Michael Takacs
MFMichael Frass
Michael Frass
GWGernot Walder
Gernot Walder
PFPhilippa Fibert
Philippa Fibert
MRMaria Rottensteiner
Maria Rottensteiner
PWPetra Weiermayer Petra Weiermayer
Petra Weiermayer Petra Weiermayer

1 December 2014 in International Journal of Surgery
Verified
Journal Article
Closed access
PPPeter Panhofer
Peter Panhofer
CRClaudia Ringhofer
Claudia Ringhofer
AGAndreas Gleiss
Andreas Gleiss
RJRaimund Jakesz
Raimund Jakesz
MPManfred Prager
Manfred Prager
CNChristoph Neumayer
Christoph Neumayer
Limited procedures at the T4 ganglion show low rates of compensatory sweating (CS). The aim of the study was to compare endoscopic sympathetic block (ESB) via clip application with endothoracic sympathicotomy (ETS) via diathermy with special regard on patients' quality of life (Qol). Treatment success, side effects and patient satisfaction were evaluated in a prospectively gathered database of a tertiary-care referral hospital. Two disease-specific Qol questionnaires were used (Keller, Milanez de Campos). 406 operations were performed in 205 patients (ESB4 N = 114, ETS4 N = 91) with a median follow-up of 12 months. Both procedures improved Qol significantly (P < 0.001) and the degree of improvement was equal in both groups. Palmar and axillary HH were ameliorated after both procedures (P < 0.001). Accordingly, plantar HH decreased after ESB4 (P = 0.002), while remaining unaltered after ETS4. Nineteen patients (9.3%) reported CS and 10 patients (4.9%) judged it as "disturbing". Nine of the latter belonged to the ETS4 group compared to one ESB patient (P = 0.015). Patients developed higher rates of plantar CS after ETS4 compared to ESB4 (P = 0.006). Five patients (2.4%) from both cohorts reported persistence of axillary HH. Recurrence of axillary symptoms was found in 5 ESB4 patients. Satisfaction rates did not differ significantly. Patients' Qol and satisfaction rates are similar in both treatment groups for upper limb HH. Outcome and recurrence rates speak in the favor of ETS4, severity of CS and potential reversibility argue for ESB4.